Scinai Signs $5.1M Manufacturing Agreement with U.S. Biopharma Firm

Key Facts

1Scinai Immunotherapeutics signed a $5.1 million development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company.

2The company's committed customer orders increased by approximately 300% to $7.6 million compared to year-end 2025.

Scinai Immunotherapeutics signed a $5.1 million development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. PR Newswire reported that the agreement is intended to support development activities in 2026, with clinical manufacturing planned for 2027 as part of the expansion of Scinai's CDMO business unit.

The company's committed customer orders increased by approximately 300% to $7.6 million, up from $1.9 million at the end of 2025. Regarding market performance, SCNI closed at $1.16 on October 12, 2026, with the stock trading between a day low of $1.11 and a high of $1.2 during that session.